Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
4 "Mee Soo Chang"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study
Haeryoung Kim, Soyeon An, Kyoungbun Lee, Sangjeong Ahn, Do Youn Park, Jo-Heon Kim, Dong-Wook Kang, Min-Ju Kim, Mee Soo Chang, Eun Sun Jung, Joon Mee Kim, Yoon Jung Choi, So-Young Jin, Hee Kyung Chang, Mee-Yon Cho, Yun Kyung Kang, Myunghee Kang, Soomin Ahn, Youn Wha Kim, Seung-Mo Hong, on behalf of the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists
Cancer Res Treat. 2020;52(1):263-276.   Published online July 12, 2019
DOI: https://doi.org/10.4143/crt.2019.192
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The most recent 2017 World Health Organization (WHO) classification of pancreatic neuroendocrine neoplasms (PanNENs) has refined the three-tiered 2010 scheme by separating grade 3 pancreatic neuroendocrine tumors (G3 PanNETs) from poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs). However, differentiating between G3 Pan- NETs and PanNECs is difficult in clinical practice.
Materials and Methods
Eighty-two surgically resected PanNENs were collected from 16 institutions and reclassified according to the 2017 WHO classification based on the histological features and proliferation index (mitosis and Ki-67). Immunohistochemical stains for ATRX, DAXX, retinoblastoma, p53, Smad4, p16, and MUC1 were performed for 15 high-grade PanNENs.
Results
Re-classification resulted in 20 G1 PanNETs (24%), 47 G2 PanNETs (57%), eight G3 well-differentiated PanNETs (10%), and seven poorly differentiated PanNECs (9%). PanNECs showed more frequent diffuse nuclear atypia, solid growth patterns and apoptosis, less frequent organoid growth and regular vascular patterns, and absence of low-grade PanNET components than PanNETs. The Ki-67 index was significantly higher in PanNEC (58.2%± 15.1%) compared to G3 PanNET (22.6%±6.1%, p < 0.001). Abnormal expression of any two of p53, p16, MUC1, and Smad4 could discriminate PanNECs from G3 PanNETs with 100% specificity and 87.5% sensitivity.
Conclusion
Histological features supporting the diagnosis of PanNECs over G3 PanNETs were the absence of a low-grade PanNET component in the tumor, the presence of diffuse marked nuclear atypia, solid growth pattern, frequent apoptosis and markedly increased proliferative activity with homogeneous Ki-67 labeling. Immunohistochemical stains for p53, p16, MUC1, and Smad4 may be helpful in distinguishing PanNECs from G3 PanNETs in histologically ambiguous cases, especially in diagnostic practice when only small biopsied tissues are available.

Citations

Citations to this article as recorded by  
  • Building a diagnostic scoring system for high-grade neuroendocrine neoplasms of the pancreas
    Yuko Kinowaki, Charlotte Wang, Yuki Fukumura, Maria Ganci, M Lisa Zhang, Masanori Kobayashi, Keiichi Akahoshi, Atsushi Kudo, Keiichi Kinowaki, Keita Kai, Yumi Mihara, Ayumi Murakami, Hung Ngoc Nguyen, Ryoichi Hanazawa, Akihiro Hirakawa, Liang Minggao, Mor
    Am J Clin Pathol.2026;[Epub]     CrossRef
  • Treatment status, survival and gene expression analysis of large-cell neuroendocrine lung carcinoma: a real-world study in China
    Fei Qi, Minghang Zhang, Yi Han, Juan Du, Hongjie Yang, Hongmei Zhang, Yong Zhang, Tongmei Zhang
    Therapeutic Advances in Medical Oncology.2025;[Epub]     CrossRef
  • Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis
    Matteo Tacelli, Manuel Gentiluomo, Paolo Biamonte, Justo P. Castano, Maja Cigrovski Berković, Mauro Cives, Sanja Kapitanović, Ilaria Marinoni, Sonja Marinovic, Ilias Nikas, Lenka Nosáková, Sergio Pedraza-Arevalo, Eleonora Pellè, Aurel Perren, Jonathan Str
    Seminars in Cancer Biology.2025; 112: 112.     CrossRef
  • Differentiation between G3 pancreatic neuroendocrine tumor and pancreatic neuroendocrine carcinoma based on intratumor and peritumor CT value ratio and abnormal vascular network
    Chaoyang Zhang, Wei Hao
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Malignant potential of neuroendocrine microtumor of the pancreas harboring high-grade transformation: lesson learned from a patient with von Hippel-Lindau syndrome
    Jongwon Lee, Kyung Jin Lee, Dae Wook Hwang, Seung-Mo Hong
    Journal of Pathology and Translational Medicine.2024; 58(2): 91.     CrossRef
  • Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation
    Atsuko Kasajima, Nicole Pfarr, Eva-Maria Mayr, Ayako Ura, Elisa Moser, Alexander von Werder, Abbas Agaimy, Marianne Pavel, Günter Klöppel
    Endocrine Pathology.2024; 35(4): 313.     CrossRef
  • The Complex Histopathological and Immunohistochemical Spectrum of Neuroendocrine Tumors—An Overview of the Latest Classifications
    Ancuța-Augustina Gheorghișan-Gălățeanu, Andreea Ilieșiu, Ioana Maria Lambrescu, Dana Antonia Țăpoi
    International Journal of Molecular Sciences.2023; 24(2): 1418.     CrossRef
  • All Together Now
    Pari Jafari, Aliya N. Husain, Namrata Setia
    Surgical Pathology Clinics.2023; 16(1): 131.     CrossRef
  • A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors
    Mauro D. Donadio, Ângelo B. Brito, Rachel P. Riechelmann
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus
    Tomoyuki Okumura, Tsutomu Fujii, Kenji Terabayashi, Takashi Kojima, Shigeru Takeda, Tomomi Kashiwada, Kazuhiro Toriyama, Susumu Hijioka, Tatsuya Miyazaki, Miho Yamamoto, Shunsuke Tanabe, Yasuhiro Shirakawa, Masayuki Furukawa, Yoshitaka Honma, Isamu Hoshin
    Oncology Letters.2023;[Epub]     CrossRef
  • The association between jaundice and poorly differentiated pancreatic neuroendocrine neoplasms (Ki67 index > 55.0%)
    Yongkang Liu, Jiangchuan Wang, Hao Zhou, Zicheng Wei, Jianhua Wang, Zhongqiu Wang, Xiao Chen
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features
    Atsuko Kasajima, Björn Konukiewitz, Anna Melissa Schlitter, Wilko Weichert, Günter Klöppel
    Virchows Archiv.2022; 480(2): 359.     CrossRef
  • An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms
    Tiago Bordeira Gaspar, José Manuel Lopes, Paula Soares, João Vinagre
    Endocrine-Related Cancer.2022; 29(12): R191.     CrossRef
  • Solid pancreatic masses in children: A review of current evidence and clinical challenges
    Kelli N. Patterson, Andrew T. Trout, Archana Shenoy, Maisam Abu-El-Haija, Jaimie D. Nathan
    Frontiers in Pediatrics.2022;[Epub]     CrossRef
  • Neuroendocrine Carcinomas with Atypical Proliferation Index and Clinical Behavior: A Systematic Review
    Tiziana Feola, Roberta Centello, Franz Sesti, Giulia Puliani, Monica Verrico, Valentina Di Vito, Cira Di Gioia, Oreste Bagni, Andrea Lenzi, Andrea M. Isidori, Elisa Giannetta, Antongiulio Faggiano
    Cancers.2021; 13(6): 1247.     CrossRef
  • Risk of cancer in patients with recurrent aphthous stomatitis in Korea
    Ki Jin Kwon, Su Jin Jeong, Young-Gyu Eun, In Hwan Oh, Young Chan Lee
    Medicine.2021; 100(16): e25628.     CrossRef
  • Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions
    Anna Pellat, Anne Ségolène Cottereau, Lola-Jade Palmieri, Philippe Soyer, Ugo Marchese, Catherine Brezault, Romain Coriat
    Cancers.2021; 13(10): 2448.     CrossRef
  • Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
    Anna Pellat, Anne Ségolène Cottereau, Benoit Terris, Romain Coriat
    Cancers.2021; 13(15): 3766.     CrossRef
  • Pancreatic Masses in Children and Young Adults: Multimodality Review with Pathologic Correlation
    Lisa Qiu, Andrew T. Trout, Rama S. Ayyala, Sara Szabo, Jaimie D. Nathan, James I. Geller, Jonathan R. Dillman
    RadioGraphics.2021; 41(6): 1766.     CrossRef
  • CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms


    Xin Chen, Chuangen Guo, Wenjing Cui, Ke Sun, Zhongqiu Wang, Xiao Chen
    Cancer Management and Research.2020; Volume 12: 4625.     CrossRef
  • Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
    Lingaku Lee, Tetsuhide Ito, Robert T Jensen
    Expert Review of Anticancer Therapy.2019; 19(12): 1029.     CrossRef
  • 13,210 View
  • 326 Download
  • 19 Web of Science
  • 21 Crossref
Close layer
FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation
Jinju Park, Yiseul Choi, Young San Ko, Younghoon Kim, Jung-Soo Pyo, Bo Gun Jang, Min A Kim, Jae-Seon Lee, Mee Soo Chang, Jong-Wan Park, Byung Lan Lee
Cancer Res Treat. 2018;50(1):239-254.   Published online March 24, 2017
DOI: https://doi.org/10.4143/crt.2016.580
AbstractAbstract PDFPubReaderePub
Purpose
Lapatinib is a candidate drug for treatment of trastuzumab-resistant, human epidermal growth factor receptor 2 (HER2)–positive gastric cancer (GC). Unfortunately, lapatinib resistance renders this drug ineffective. The present study investigated the implication of forkhead box O1 (FOXO1) signaling in the acquired lapatinib resistance in HER2-positive GC cells.
Materials and Methods
Lapatinib-resistant GC cell lines (SNU-216 LR2-8) were generated in vitro by chronic exposure of lapatinib-sensitive, HER2-positive SNU-216 cells to lapatinib. SNU-216 LR cells with FOXO1 overexpression were generated by stable transfection of a constitutively active FOXO1 mutant (FOXO1A3). HER2 and MET in SNU-216 LR cells were downregulated using RNA interference. The sensitivity of GC cells to lapatinib and/or cisplatin was determined by crystal violet assay. In addition, Western blot analysis, luciferase reporter assay and reverse transcription–polymerase chain reaction were performed.
Results
SNU-216 LR cells showed upregulations of HER2 and MET, but downregulation of FOXO1 compared to parental SNU-216 cells. FOXO1 overexpression in SNU-216 LR cells significantly suppressed resistance to lapatinib and/or cisplatin. In addition, FOXO1 negatively controlled HER2 and MET at the transcriptional level and was negatively controlled by these molecules at the post-transcriptional level. A positive crosstalk was shown between HER2 and MET, each of which increased resistance to lapatinib and/or cisplatin.
Conclusion
FOXO1 serves as an important linker between HER2 and MET signaling pathways through negative crosstalks and is a key regulator of the acquired lapatinib resistance in HER2-positive GC cells. These findings provide a rationale for establishing a novel treatment strategy to overcome lapatinib resistance in a subtype of GC patients.

Citations

Citations to this article as recorded by  
  • Correspondence to Editorial 2 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
    Tiantian Wang, Wenjie Huang, Limin Xia
    Clinical and Molecular Hepatology.2026; 32(1): e93.     CrossRef
  • Correspondence to Editorial 1 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
    Tiantian Wang, Wenjie Huang, Limin Xia
    Clinical and Molecular Hepatology.2026; 32(1): e90.     CrossRef
  • Unveiling TRIB3: A new mediator in MET-driven hepatocellular carcinoma progression: Editorial on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
    Many Sze Man Chan, Terence Kin Wah Lee
    Clinical and Molecular Hepatology.2026; 32(1): 432.     CrossRef
  • The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer
    Qiu-yun Luo, Jing Yang, Tian Di, Zeng-fei Xia, Lin Zhang, Wen-tao Pan, Shan Shi, Li-qiong Yang, Jian Sun, Miao-zhen Qiu, Da-jun Yang
    Acta Pharmacologica Sinica.2025; 46(4): 1082.     CrossRef
  • FoxO1 Deficiency in Monocytic Myeloid‐Derived Suppressor Cells Exacerbates B Cell Dysfunction in Systemic Lupus Erythematosus
    Liping Tan, Wei Kong, Kangxing Zhou, Shuangan Wang, Jun Liang, Yayi Hou, Huan Dou
    Arthritis & Rheumatology.2025; 77(4): 423.     CrossRef
  • MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation
    Tiantian Wang, Dean Rao, Chenan Fu, Zhoubin Sun, Yiming Luo, Junli Lu, Jie Jin, Han Li, Feimu Fan, Huifang Liang, Wenjie Huang, Limin Xia
    Clinical and Molecular Hepatology.2025; 31(3): 1032.     CrossRef
  • The FOXO1/G6PC axis promotes gastric cancer progression and mediates 5‐fluorouracil resistance by targeting the PI3K/AKT/mTOR signaling pathway
    Anna Han, Taorui Liu, Pan Du, Mengying Wang, Jiajing Liu, Liyan Chen
    Molecular Carcinogenesis.2024; 63(4): 688.     CrossRef
  • Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy
    Jin-Soo Kim, Mi Young Kim, Sungyoul Hong
    International Journal of Molecular Sciences.2024; 25(11): 5975.     CrossRef
  • HER2-targeted therapies beyond breast cancer — an update
    Jeesun Yoon, Do-Youn Oh
    Nature Reviews Clinical Oncology.2024; 21(9): 675.     CrossRef
  • Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
    Christiana Mo, Michelle Sterpi, Hyein Jeon, Fernand Bteich
    Cancers.2024; 16(16): 2854.     CrossRef
  • Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
    Maluki Radford, Hassan Abushukair, Stijn Hentzen, Ludimila Cavalcante, Anwaar Saeed
    Journal of Immunotherapy and Precision Oncology.2023; 6(3): 150.     CrossRef
  • Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review
    Dionne Blangé, Charlotte I. Stroes, Sarah Derks, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven
    Cancer Treatment Reviews.2022; 108: 102418.     CrossRef
  • The FOXO family of transcription factors: key molecular players in gastric cancer
    Ying Liu, Xiang Ao, Yi Jia, Xiaoge Li, Yu Wang, Jianxun Wang
    Journal of Molecular Medicine.2022; 100(7): 997.     CrossRef
  • VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-β/ERK/RSK2 signaling
    Joo-Young Im, Da-Mi Kim, Hyunkyung Park, Mi-Jung Kang, Da-Yoon Kim, Kwan Young Chang, Bo-Kyung Kim, Misun Won
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2021; 1868(1): 118892.     CrossRef
  • The efficacy and safety of onartuzumab in patients with solid cancers: A meta-analysis of randomized trials
    BumJun Kim, Dalyong Kim, JungHan Kim, HyeongSu Kim, HyunJoo Jang
    Indian Journal of Cancer.2021; 58(2): 232.     CrossRef
  • HER2-targeted therapies in gastric cancer
    Yinxing Zhu, Xuedan Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2021; 1876(1): 188549.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Diverse roles of FOXO family members in gastric cancer
    Yu-Han Chen, Chun-Lan Li, Wen-Jia Chen, Jing Liu, Hua-Tao Wu
    World Journal of Gastrointestinal Oncology.2021; 13(10): 1367.     CrossRef
  • Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies
    Nehad M. Ayoub, Dalia R. Ibrahim, Amer E. Alkhalifa
    Medical Oncology.2021;[Epub]     CrossRef
  • Fertility preservation in women with ovarian cancer: Finding new pathways: A case-control study
    Ali Khodadadian, Yasser Varghaiyan, Emad Babakhanzadeh, Iraj Alipourfard, Saeed Haghi-Daredeh, Amin Ghobadi, Mohsen Hemmati-Dinarvand, Mehrdad Talebi, Nasrin Ghasemi
    International Journal of Reproductive BioMedicine (IJRM).2021; 19(2): 157.     CrossRef
  • Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/β-Catenin Pathway
    Xi Wang, Bin Lu, Chunyan Dai, Yufei Fu, Ke Hao, Bing Zhao, Zhe Chen, Li Fu
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Machine Learning-Guided Prediction of Antigen-Reactive In Silico Clonotypes Based on Changes in Clonal Abundance through Bio-Panning
    Duck Kyun Yoo, Seung Ryul Lee, Yushin Jung, Haejun Han, Hwa Kyoung Lee, Jerome Han, Soohyun Kim, Jisu Chae, Taehoon Ryu, Junho Chung
    Biomolecules.2020; 10(3): 421.     CrossRef
  • FOXO transcription factor family in cancer and metastasis
    Yannasittha Jiramongkol, Eric W.-F. Lam
    Cancer and Metastasis Reviews.2020; 39(3): 681.     CrossRef
  • In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines


    Hasaya Dokduang, Wassana Jamnongkarn, Bundit Promraksa, Manida Suksawat, Sureerat Padthaisong, Malinee Thanee, Jutarop Phetcharaburanin, Nisana Namwat, Sakkarn Sangkhamanon, Attapol Titapun, Narong Khuntikeo, Poramate Klanrit, Watcharin Loilome
    Drug Design, Development and Therapy.2020; Volume 14: 2319.     CrossRef
  • MiR-27a promotes EMT in ovarian cancer through active Wnt/
    Li-Ya Zhang, Yuan Chen, Jue Jia, Xi Zhu, Yan He, Li-Ming Wu
    Cancer Biomarkers.2019; 24(1): 31.     CrossRef
  • Role of FoxO Proteins in Cellular Response to Antitumor Agents
    Giovanni Luca Beretta, Cristina Corno, Nadia Zaffaroni, Paola Perego
    Cancers.2019; 11(1): 90.     CrossRef
  • Members of FOX family could be drug targets of cancers
    Jinhua Wang, Wan Li, Ying Zhao, De Kang, Weiqi Fu, Xiangjin Zheng, Xiaocong Pang, Guanhua Du
    Pharmacology & Therapeutics.2018; 181: 183.     CrossRef
  • FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models
    Cristina Corno, Simone Stucchi, Michelandrea De Cesare, Nives Carenini, Serena Stamatakos, Emilio Ciusani, Lucia Minoli, Eugenio Scanziani, Christian Argueta, Yosef Landesman, Nadia Zaffaroni, Laura Gatti, Paola Perego
    Biochemical Pharmacology.2018; 147: 93.     CrossRef
  • Nuclear division cycle 80 promotes malignant progression and predicts clinical outcome in colorectal cancer
    Xuebing Yan, Linsheng Huang, Liguo Liu, Huanlong Qin, Zhenshun Song
    Cancer Medicine.2018;[Epub]     CrossRef
  • Systems analysis of key genes and pathways in the progression of hepatocellular carcinoma
    Yu-Kui Shang, Fanni Li, Yi Zhang, Ze-Kun Liu, Zi-Ling Wang, Huijie Bian, Zhi-Nan Chen
    Medicine.2018; 97(23): e10892.     CrossRef
  • The Dominant Role of Forkhead Box Proteins in Cancer
    Duc-Hiep Bach, Nguyen Phuoc Long, Thi-Thu-Trang Luu, Nguyen Hoang Anh, Sung Won Kwon, Sang Kook Lee
    International Journal of Molecular Sciences.2018; 19(10): 3279.     CrossRef
  • HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
    Kang-Seo Park, Yong Sang Hong, Junyoung Choi, Shinkyo Yoon, Jihoon Kang, Deokhoon Kim, Kang-Pa Lee, Hyeon-Su Im, Chang Hoon Lee, Seyoung Seo, Sang-We Kim, Dae Ho Lee, Sook Ryun Park
    BMB Reports.2018; 51(12): 660.     CrossRef
  • FOXO1 reduces tumorsphere formation capacity and has crosstalk with LGR5 signaling in gastric cancer cells
    Yiseul Choi, Jinju Park, Young San Ko, Younghoon Kim, Jung-Soo Pyo, Bo Gun Jang, Min A Kim, Jae-Seon Lee, Mee Soo Chang, Byung Lan Lee
    Biochemical and Biophysical Research Communication.2017; 493(3): 1349.     CrossRef
  • Trifluoperazine Activates FOXO1-Related Signals to Inhibit Tumor Growth in Hepatocellular Carcinoma
    Jingwen Jiang, Zhongxi Huang, Xuewu Chen, Rongcheng Luo, Hongbin Cai, Hairu Wang, Hui Zhang, Tao Sun, Yunfang Zhang
    DNA and Cell Biology.2017; 36(10): 813.     CrossRef
  • 14,519 View
  • 388 Download
  • 34 Web of Science
  • 34 Crossref
Close layer
Review Article
Epstein-Barr Virus in Human Malignancy: A Special Reference to Epstein-Barr Virus associated Gastric Carcinoma
Mee Soo Chang, Woo Ho Kim
Cancer Res Treat. 2005;37(5):257-267.   Published online October 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.5.257
AbstractAbstract PDFPubReaderePub

Epstein-Bar virus (EBV), a human herpesvirus, establishes a life-long persistent infection in 90~95% of human adult population worldwide. EBV is the etiologic agent of infectious mononucleosis, and EBV is associated with a variety of human malignancy including lymphoma and gastric carcinoma. Recently, EBV has been classified as group 1 carcinogen by the WHO International Agency for Research on Cancer. Evidence is presented which suggests that failures of the EBV-specific immunity may play a role in the pathogenesis of EBV-associated malignancy. At present, the precise mechanisms by which EBV transforms B lymphocytes have been disclosed. Encouragingly, they have had enough success so far to keep them enthusiastic about novel therapeutic trial in the field of EBV-associated lymphoma. However, information on EBV-associated gastric carcinoma is still at dawn. This article reviews EBV biology, immunological response of EBV infection, unique oncogenic property of EBV, peculiarity of EBV-associated gastric carcinoma, and lastly, EBV-targeted therapy and vaccination.

Citations

Citations to this article as recorded by  
  • A System-Level Perspective on Epstein–Barr Virus Persistence: The Partial Lytic Reactivation
    Krzysztof Piotr Michalak, Wojciech Adamski
    International Journal of Molecular Sciences.2026; 27(7): 3337.     CrossRef
  • Current development of therapeutic vaccines for the treatment of chronic infectious diseases
    Pil-Gu Park, Munazza Fatima, Timothy An, Ye-Eun Moon, Seungkyun Woo, Hyewon Youn, Kee-Jong Hong
    Clinical and Experimental Vaccine Research.2024; 13(1): 21.     CrossRef
  • Cutaneous Post-transplant Lymphoproliferative Disorder
    Alpa Kanji, Raida Ahmad, Laksha Bala, Eleanor Mallon
    Cureus.2024;[Epub]     CrossRef
  • Clinicopathologic Characteristics of Trop Family Proteins (Trop-2 and EpCAM) in Gastric Carcinoma
    Hye Sung Kim, Younghoon Kim, Hye Seung Lee
    Journal of Gastric Cancer.2024; 24(4): 391.     CrossRef
  • Características clínico-patológicas del adenocarcinoma gástrico asociado al virus de Epstein-Barr en una región de alta incidencia de cáncer gástrico en Colombia
    A. Vidal-Realpe, R.A. Dueñas-Cuellar, V.E. Niño-Castaño, D.L. Mora-Obando, J.J. Arias-Agudelo, H.J. Bolaños
    Revista de Gastroenterología de México.2023; 88(3): 256.     CrossRef
  • Clinical and pathologic characteristics of gastric adenocarcinoma associated with Epstein-Barr virus in a region with a high incidence of gastric cancer in Colombia
    A. Vidal-Realpe, R.A. Dueñas-Cuellar, V.E. Niño-Castaño, D.L. Mora-Obando, J.J. Arias-Agudelo, H.J. Bolaños
    Revista de Gastroenterología de México (English Edition).2023; 88(3): 256.     CrossRef
  • Iroquois Family Genes in Gastric Carcinogenesis: A Comprehensive Review
    Everton Cruz dos Santos, Igor Petrone, Renata Binato, Eliana Abdelhay
    Genes.2023; 14(3): 621.     CrossRef
  • The role of viruses in cancer development versus cancer therapy: An oncological perspective
    Hossein Javid, Alireza Sharbaf Mashhad, Shaghayegh Yazdani, Mahsa Akbari Oryani, Sanaz Akbari, Nastaran Rezagholinejad, Mahboubeh Tajaldini, Mehdi Karimi‐Shahri
    Cancer Medicine.2023; 12(10): 11127.     CrossRef
  • Could Immune Checkpoint Disorders and EBV Reactivation Be Connected in the Development of Hematological Malignancies in Immunodeficient Patients?
    Paulina Mertowska, Sebastian Mertowski, Konrad Smolak, Gabriela Kita, Katarzyna Guz, Aleksandra Kita, Marcin Pasiarski, Jolanta Smok-Kalwat, Stanisław Góźdź, Ewelina Grywalska
    Cancers.2023; 15(19): 4786.     CrossRef
  • The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development
    Maria Lina Tornesello, Andrea Cerasuolo, Noemy Starita, Anna Lucia Tornesello, Patrizia Bonelli, Franca Maria Tuccillo, Luigi Buonaguro, Maria G. Isaguliants, Franco M. Buonaguro
    Cancers.2022; 14(21): 5257.     CrossRef
  • Epstein-Barr Virus Positive Mucocutaneous Ulceration: A case report
    Hiraa Javed, Parkash L. Ramchandani
    Advances in Oral and Maxillofacial Surgery.2021; 4: 100205.     CrossRef
  • Recent Advances in Diagnostic Approaches for Epstein–Barr Virus
    Mai Abdel Haleem Abusalah, Siew Hua Gan, Mohammad A. I. Al-Hatamleh, Ahmad Adebayo Irekeola, Rafidah Hanim Shueb, Chan Yean Yean
    Pathogens.2020; 9(3): 226.     CrossRef
  • Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia
    Evita Gasenko, Sergejs Isajevs, Maria Constanza Camargo, George Johan A. Offerhaus, Inese Polaka, Margaret L. Gulley, Roberts Skapars, Armands Sivins, Ilona Kojalo, Arnis Kirsners, Daiga Santare, Jelizaveta Pavlova, Olga Sjomina, Elina Liepina, Liliana Tz
    European Journal of Gastroenterology & Hepatology.2019; 31(11): 1328.     CrossRef
  • Low CD4 cells and viral co-infection increase the risk of VaIN: Use of SCCA1 and Ki67 as diagno-prognostic biomarkers
    Jude Ogechukwu Okoye, Charles Erinle, Antony Ajuluchukwu Ngokere, Abimbola Jimoh
    Pathophysiology.2018; 25(1): 51.     CrossRef
  • Epigenetic Regulation of Tumor Suppressors byHelicobacter pyloriEnhances EBV-Induced Proliferation of Gastric Epithelial Cells
    Saurabh Pandey, Hem Chandra Jha, Sanket Kumar Shukla, Meghan K. Shirley, Erle S. Robertson, Terence S. Dermody, Blossom Damania, Bala Chandran, Shou-Jiang Gao
    mBio.2018;[Epub]     CrossRef
  • Phylogenetic comparison of Epstein-Barr virus genomes
    Su Jin Choi, Seok Won Jung, Sora Huh, Hyosun Cho, Hyojeung Kang
    Journal of Microbiology.2018; 56(8): 525.     CrossRef
  • Regulation of proliferation and invasion by the IGF signalling pathway in Epstein‐Barr virus‐positive gastric cancer
    Inhye Jeong, Sun Kyoung Kang, Woo Sun Kwon, Hyun Jeong Kim, Kyoo Hyun Kim, Hyun Myong Kim, Andre Lee, Suk Kyeong Lee, Thomas Bogenrieder, Hyun Cheol Chung, Sun Young Rha
    Journal of Cellular and Molecular Medicine.2018; 22(12): 5899.     CrossRef
  • A common molecular signature of intestinal-type gastric carcinoma indicates processes related to gastric carcinogenesis
    Renata Binato, Everton Cruz Santos, Mariana Boroni, Samia Demachki, Paulo Assumpção, Eliana Abdelhay
    Oncotarget.2018; 9(7): 7359.     CrossRef
  • Development of lymphoma from the donor of haploidentical stem cell transplantation: A case report
    Linna Xie, Fang Zhou
    Molecular and Clinical Oncology.2017; 7(5): 851.     CrossRef
  • Implication of Leptin-Signaling Proteins and Epstein-Barr Virus in Gastric Carcinomas
    Euno Choi, Sun-ju Byeon, Soo Hee Kim, Hyun Ju Lee, Hyeong Ju Kwon, HyeSeong Ahn, Dong Ha Kim, Mee Soo Chang, Joseph S Pagano
    PLOS ONE.2015; 10(7): e0130839.     CrossRef
  • Epstein Barr Virus and Helicobacter pylori Co-Infection Are Positively Associated with Severe Gastritis in Pediatric Patients
    María G. Cárdenas-Mondragón, Ricardo Carreón-Talavera, Margarita Camorlinga-Ponce, Alejandro Gomez-Delgado, Javier Torres, Ezequiel M. Fuentes-Pananá, Yoshio Yamaoka
    PLoS ONE.2013; 8(4): e62850.     CrossRef
  • Cell cycle regulators, APC/β-catenin, NF-κB and Epstein-Barr virus in gastric carcinomas
    Bomi Kim, Sun-Ju Byun, Young A. Kim, Ji Eun Kim, Byung Lan Lee, Woo Ho Kim, Mee Soo Chang
    Pathology.2010; 42(1): 58.     CrossRef
  • Clinical Characteristics of Monomorphic Post-transplant Lymphoproliferative Disorders
    Jung-Hye Choi, Byeong-Bae Park, Cheolwon Suh, Jong-Ho Won, Won-Sik Lee, Ho-Jin Shin
    Journal of Korean Medical Science.2010; 25(4): 523.     CrossRef
  • Epstein–Barr virus antibody level and gastric cancer risk in Korea: a nested case–control study
    Y Kim, A Shin, J Gwack, K-P Ko, C-S Kim, S K Park, Y-C Hong, D Kang, K-Y Yoo
    British Journal of Cancer.2009; 101(3): 526.     CrossRef
  • Nuclear Factor-Kappa B Inhibition Reduces Markedly Cell Proliferation in Epstein-Barr Virus-Infected Stomach Cancer, But Affects Variably in Epstein-Barr Virus-Negative Stomach Cancer
    Jin-Yong Jeong, Jun Hee Woo, Yang Soo Kim, Sangho Choi, Sang Oh Lee, Seol-Ryoung Kil, Chul Woo Kim, Byung Lan Lee, Woo Ho Kim, Byung-Ho Nam, Mee Soo Chang
    Cancer Investigation.2009; 28(2): 113.     CrossRef
  • 20,410 View
  • 111 Download
  • 25 Crossref
Close layer
Original Article
Prognostic Significance of CD24 Expression in Gastric Carcinoma
Nevine S. Darwish, Min A Kim, Mee Soo Chang, Hye Seung Lee, Byung Lan Lee, Yong Il Kim, Woo Ho Kim
Cancer Res Treat. 2004;36(5):298-302.   Published online October 30, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.298
AbstractAbstract PDFPubReaderePub
Purpose

The human CD24 antigen is a small heavily glycosylated cell surface protein, which is expressed in hematological malignancies, as well as in a large variety of solid tumors. Its expression is now known to be related to the prognosis of several kinds of tumors. This study is designed to examine the prognostic significance of CD24 in Korean gastric cancer patients.

Materials and Methods

In the present study, we examined CD24 expression in 300 consecutive cases of gastric carcinoma by immunohistochemical staining using the tissue-array method. We also investigated the clinicopathological profiles related to CD24 expression.

Results

One hundred and three cases out of 300 (34.3%) showed the positive expression of CD24. The altered expression of CD24 was significantly associated with differentiated cancer (p=0.003), the intestinal subtype according to the Lauren classification (p<0.001), the advanced stage cancer (p=0.027), with lymphatic invasion (p=0.038) and with vascular invasion (p=0.006). The survival analysis revealed that the patients with CD24 positive expression showed significantly poorer survival than those without CD24 expression. Moreover, a combined evaluation revealed that PTEN+/CD24- cases showed the best survival compared to other groups (p=0.01).

Conclusion

Positive CD24 expression occurs in a subset of gastric carcinomas and it correlates significantly with lymphatic invasion, blood vessel invasion and poor survival.

Citations

Citations to this article as recorded by  
  • CD24 blockade as a novel strategy for cancer treatment
    Yawen Wang, Haoran Yu, Mengyuan Yu, Hui Liu, Bing Zhang, Yuanyuan Wang, Simin Zhao, Qingxin Xia
    International Immunopharmacology.2023; 121: 110557.     CrossRef
  • Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200
    Sun Young Moon, Minjoo Han, Gyoungah Ryu, Seong-Ah Shin, Jun Hyuck Lee, Chang Sup Lee
    International Journal of Molecular Sciences.2023; 24(20): 15072.     CrossRef
  • Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis
    Mahdieh Razmi, Roya Ghods, Somayeh Vafaei, Maryam Sahlolbei, Leili Saeednejad Zanjani, Zahra Madjd
    Cancer Cell International.2021;[Epub]     CrossRef
  • Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids
    Michel Vidal
    Advanced Drug Delivery Reviews.2020; 161-162: 110.     CrossRef
  • CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy
    Yang-Hong Ni, Xia Zhao, Wei Wang
    Current Gene Therapy.2020; 20(2): 109.     CrossRef
  • DNA Aptamers for the Malignant Transformation Marker CD24
    Joanna Fafińska, Andreas Czech, Tobias Sitz, Zoya Ignatova, Ulrich Hahn
    Nucleic Acid Therapeutics.2018; 28(6): 326.     CrossRef
  • The Identifications and Clinical Implications of Cancer Stem Cells in Colorectal Cancer
    S.M. Riajul Wahab, Farhadul Islam, Vinod Gopalan, Alfred King-yin Lam
    Clinical Colorectal Cancer.2017; 16(2): 93.     CrossRef
  • Clinicopathological and Prognostic Value of CD24 Expression in Breast Cancer: A Meta-Analysis
    Gao Liu, Guo-Xing Liu, Yu Fang, Zhen-Yu Cao, Hui-Hui Du, Jie Fu, Ke Qian
    The International Journal of Biological Markers.2017; 32(2): 182.     CrossRef
  • CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells
    Wenjie Deng, Luo Gu, Xiaojie Li, Jianchao Zheng, Yujie Zhang, Biao Duan, Jie Cui, Jing Dong, Jun Du
    Journal of Translational Medicine.2016;[Epub]     CrossRef
  • CD24 enrichment protects while its loss increases susceptibility of juvenile chondrocytes towards inflammation
    Jieun Lee, Piera Smeriglio, Jason Dragoo, William J. Maloney, Nidhi Bhutani
    Arthritis Research & Therapy.2016;[Epub]     CrossRef
  • CD44v3+/CD24− cells possess cancer stem cell-like properties in human oral squamous cell carcinoma
    KEITA TODOROKI, SACHIKO OGASAWARA, JUN AKIBA, MASAMICHI NAKAYAMA, YOSHIKI NAITO, NAOKO SEKI, JINGO KUSUKAWA, HIROHISA YANO
    International Journal of Oncology.2016; 48(1): 99.     CrossRef
  • CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation
    Yao-An Shen, Chia-Yu Wang, Hui-Yen Chuang, John Jeng-Jong Hwang, Wei-Hsin Chi, Chih-Hung Shu, Ching-Yin Ho, Wing-Yin Li, Yann-Jang Chen
    Oncotarget.2016; 7(36): 58351.     CrossRef
  • CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer
    Mi Jeong Kwon, Jinil Han, Ji Hyun Seo, Kyoung Song, Hae Min Jeong, Jong-Sun Choi, Yu Jin Kim, Seon-Heui Lee, Yoon-La Choi, Young Kee Shin, Yves St-Pierre
    PLOS ONE.2015; 10(10): e0139112.     CrossRef
  • Significance of the expression of EMMPRIN, CD24 and p16INK4a promoter methylation in gastric carcinoma
    Ahlam A. AbdelMaksoud
    Egyptian Journal of Pathology.2015; 35(1): 53.     CrossRef
  • Expression of CD24, p21, p53, and c‐myc in alpha‐fetoprotein‐producing gastric cancer: Correlation with clinicopathologic characteristics and survival
    Xiaowen Liu, Hongmei Yu, Hong Cai, Yanong Wang
    Journal of Surgical Oncology.2014; 109(8): 859.     CrossRef
  • CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation
    Ying-Chao Wang, Ji-Lin Wang, Xuan Kong, Tian-Tian Sun, Hao-Yan Chen, Jie Hong, Jing-Yuan Fang
    Apoptosis.2014; 19(4): 643.     CrossRef
  • CD44 but not CD24 expression is related to poor prognosis in non-cardia adenocarcinoma of the stomach
    Xueyuan Cao, Donghui Cao, MeiShan Jin, Zhifang Jia, Fei Kong, Hongxi Ma, Yinping Wang, Jing Jiang
    BMC Gastroenterology.2014;[Epub]     CrossRef
  • Hypoxia‐mediated CD24 expression is correlated with gastric cancer aggressiveness by promoting cell migration and invasion
    Nobuaki Fujikuni, Hideki Yamamoto, Kazuaki Tanabe, Yutaka Naito, Naoya Sakamoto, Yuka Tanaka, Kazuyoshi Yanagihara, Naohide Oue, Wataru Yasui, Hideki Ohdan
    Cancer Science.2014; 105(11): 1411.     CrossRef
  • Clinicopathological and Prognostic Significance of CD24 Overexpression in Patients with Gastric Cancer: A Meta-Analysis
    Jing-Xun Wu, Yuan-Yuan Zhao, Xuan Wu, Han-Xiang An, Yitao Ding
    PLoS ONE.2014; 9(12): e114746.     CrossRef
  • Biomarkers for predicting future metastasis of human gastrointestinal tumors
    Lui Ng, Ronnie Tung Ping Poon, Roberta Pang
    Cellular and Molecular Life Sciences.2013; 70(19): 3631.     CrossRef
  • CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
    Ching-Shya Yong, Chih-Ming Ou Yang, Yenn-Hwei Chou, Chao-Sheng Liao, Chung-Wei Lee, Chin-Cheng Lee
    BMC Gastroenterology.2012;[Epub]     CrossRef
  • PTEN deletion is rare but often homogeneous in gastric cancer
    Sormeh Mina, Benjamin A Bohn, Ronald Simon, Antje Krohn, Matthias Reeh, Dirk Arnold, Carsten Bokemeyer, Guido Sauter, Jakob R Izbicki, Andreas Marx, Phillip R Stahl
    Journal of Clinical Pathology.2012; 65(8): 693.     CrossRef
  • Prognostic significance of loss of c-fos protein in gastric carcinoma
    Seon Pil Jin, Ji Hun Kim, Min A Kim, Han-Kwang Yang, Hee Eun Lee, Hye Seung Lee, Woo Ho Kim
    Pathology & Oncology Research.2007; 13(4): 284.     CrossRef
  • Tissue Array Methods for High-throughput Clinicopathologic Research
    Hye Seung Lee, Woo Ho Kim
    Cancer Research and Treatment.2006; 38(1): 1.     CrossRef
  • Loss of DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) Expression in Gastric Cancers
    Hye Seung Lee, Han-Kwang Yang, Woo Ho Kim, Gheeyoung Choe
    Cancer Research and Treatment.2005; 37(2): 98.     CrossRef
  • Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival
    Wilko Weichert, Carsten Denkert, Mick Burkhardt, Tserenchunt Gansukh, Joachim Bellach, Peter Altevogt, Manfred Dietel, Glen Kristiansen
    Clinical Cancer Research.2005; 11(18): 6574.     CrossRef
  • 11,175 View
  • 61 Download
  • 26 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP